Navigation Links
Is prenatal screening for rare diseases like spinal muscular atrophy too costly?
Date:3/8/2010

New York, NY, March 8, 2010 Spinal Muscular Atrophy (SMA) is one of many serious disorders for which prenatal testing is available. SMA affects approximately 1 in 10,000 live births and is the leading genetic cause of infant mortality and the second most common autosomal recessive disorder, after cystic fibrosis. Although the American College of Medical Genetics recommends carrier testing for all couples, the American College of Obstetricians and Gynecologists has issued a recommendation to the contrary, citing lack of information about the costs and benefits of screening for SMA. An article which may shed light on this controversy appears in the March 2010 issue of the American Journal of Obstetrics & Gynecology.

Using a decision analytic model, the authors found that 12,500 women need to be screened to prevent one case of SMA, at a cost of $5 million per case averted. They also determined that at $4.9 million per Quality-Adjusted Life Year (QALY), such screening was not cost-effective. Maternal QALY was used to measure the combined effects of caring for a child who suffers from the disease with resultant premature death and disability.

The cost of the procedures involved, maternal and paternal genetic testing, fetal amniocentesis and genetic testing of fetal cells, were all estimated from data published in the literature. The model assumed that couples with a positive fetal test would elect pregnancy termination. Lifetime costs of caring for an affected child were estimated from costs for similar diseases documented in the medical literature. All costs were adjusted to 2009 dollars using the Consumer Price Index.

The authors found that the cost per case averted was the most influenced by the baseline prevalence of disease in the population screened. For those couples with a higher prevalence, such as those with a family history of disease, screening may be a cost-effective strategy.

Writing in the article, Sarah E. Little, MD, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, and co-authors state that "our estimated cost per added QALY falls far beyond what is usually considered to be cost effective. SMA screening does not approach the cost-effective range ($50-100,000/QALY) until the cost of severe disease is over $7 million or the cost of the mild disease is over $17 million, both of which are more than 20 times the baseline estimates. As such, we feel there is little chance that the basic finding that universal SMA testing is not cost effective would change appreciably with different model inputs."


'/>"/>

Contact: Pamela Poppalardo
ajogmedia@elsevier.com
732-238-3628
Elsevier Health Sciences
Source:Eurekalert

Related biology news :

1. MIT: Prenatal arsenic exposure detected in newborns
2. Trainor Lab characterizes gene essential for prenatal development of nervous system
3. Moderate prenatal exposure to alcohol and stress in monkeys can cause touch sensitivity
4. Low sperm count may be associated with prenatal testosterone excess
5. Microarray analysis improves prenatal diagnosis
6. Prenatal meth exposure linked to abnormal brain development
7. How to deliver the news? New advice for doctors diagnosing prenatal Down syndrome
8. Sex-based prenatal brain differences found
9. Good parenting triumphs over prenatal stress
10. UNC study questions FDA genetic-screening guidelines for cancer drug
11. MIT: Micro livers could aid drug screening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2017)... March 20, 2017 At this year,s CeBIT Chancellor ... biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with ... this year,s CeBIT partner country. At the largest German biometrics company the ... fingerprint, face and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/16/2017)... 16, 2017 CeBIT 2017 - Against identity fraud with DERMALOG solutions ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against ... Used combined in one project, ... ...
(Date:3/9/2017)... March 9, 2017 4Dx has publicly released ... Imaging Workshop at the University of Pennsylvania. Founder and ... deliver the latest data to world leaders in lung ... together leaders at the forefront of the industry to ... "The quality of the imaging is ...
Breaking Biology News(10 mins):
(Date:4/27/2017)... and RESEARCH TRIANGLE PARK, N.C. ... Corporation (NASDAQ: UTHR ) today announced that ... to $250 million of the company,s common stock. This ... through December 31, 2017. Purchases may be made in ... negotiated transactions from time to time as determined by ...
(Date:4/27/2017)... ... April 27, 2017 , ... Mitotech S.A, a Luxembourg based ... Optic Neuropathy (LHON) patients. LHON is a rare devastating genetic disease that leads to ... drops in a group of 20 patients carrying 11778, 14484 and 3460 mutations and ...
(Date:4/27/2017)... ... April 27, 2017 , ... During the course ... how testing for 1,25-Dihydroxyvitamin D can enhance clinical practice. Participants will learn the ... dihydroxyvitamin D. , Dr. Gregory Plotnikoff, senior consultant with Minnesota Personalized Medicine, will ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... , joined other scientists, researchers, engineers, and industry professionals in visiting U.S. Congressional ... ability to compete in the world photonics industry. , This year, National ...
Breaking Biology Technology: